Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …

Bladder cancer is one of the most prevalent cancers worldwide, but the treatment and
management of this disease can be very successful if the disease is detected early. The …

Background Detecting pre-clinical bladder cancer (BC) using urinary biomarkers may
provide a valuable opportunity for screening and management. Telomerase reverse …

Purpose To validate urinary markers for the early detection of bladder cancer (BC) in
chemical workers. Methods UroScreen was conducted as a validation study for tumor …

Bladder cancer (BC) has high morbidity and mortality rates owing to challenges in clinical
diagnosis and treatment. Advanced BC is prone to recurrence after surgery, necessitating …

Clinical use of proteomic biomarkers has the potential to substantially improve the outcomes
of patients with bladder cancer. An unmet clinical need evidently exists for noninvasive …

Purpose Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a
multifunctional protein that shows elevated expression in a number of cancers. We …

Bladder cancer has the fifth highest incidence of all malignancies in the United States, with a
propensity to recur, requiring lifelong surveillance after diagnosis. Urinary markers of …

The current gold standard for the diagnosis of bladder cancer is cystoscopy, which is
invasive and painful for patients. Therefore, noninvasive urine cytology is usually used in the …

Background The commercial NMP-22 urine assays for bladder cancer (BCa) detect nuclear
mitotic apparatus protein 1 (NUMA1) using monoclonal antibodies. It remains unclear …